Aytu BioScience Inc (AYTU) - Total Liabilities
Based on the latest financial reports, Aytu BioScience Inc (AYTU) has total liabilities worth $76.55 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aytu BioScience Inc - Total Liabilities Trend (2007–2025)
This chart illustrates how Aytu BioScience Inc's total liabilities have evolved over time, based on quarterly financial data. See Aytu BioScience Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Aytu BioScience Inc Competitors by Total Liabilities
The table below lists competitors of Aytu BioScience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Euroholdings Ltd.
NASDAQ:EHLD
|
USA | $23.77 Million |
|
Newtree S.A
BR:NEWT
|
Belgium | €697.20K |
|
Richmond Vanadium Technology Ltd
AU:RVT
|
Australia | AU$1.20 Million |
|
Medhelp Care AB
ST:MEDHLP
|
Sweden | Skr28.58 Million |
|
CervoMed Inc.
NASDAQ:CRVO
|
USA | $4.50 Million |
|
Keller Group PLC
LSE:KLR
|
UK | GBX1.15 Billion |
|
Orcay Ortakoy Cay Sanayi & Ticaret AS
IS:ORCAY
|
Turkey | TL419.20 Million |
|
Indo Acidatama Tbk
JK:SRSN
|
Indonesia | Rp379.93 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Aytu BioScience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Aytu BioScience Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aytu BioScience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aytu BioScience Inc (2007–2025)
The table below shows the annual total liabilities of Aytu BioScience Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $105.21 Million | +15.44% |
| 2024-06-30 | $91.14 Million | -7.46% |
| 2023-06-30 | $98.48 Million | +5.54% |
| 2022-06-30 | $93.31 Million | -27.15% |
| 2021-06-30 | $128.10 Million | +121.55% |
| 2020-06-30 | $57.82 Million | +109.24% |
| 2019-06-30 | $27.63 Million | +261.90% |
| 2018-06-30 | $7.64 Million | -30.58% |
| 2017-06-30 | $11.00 Million | -22.86% |
| 2016-06-30 | $14.26 Million | +446.20% |
| 2015-06-30 | $2.61 Million | -60.73% |
| 2014-06-30 | $6.65 Million | +5414.78% |
| 2013-06-30 | $120.53K | +46.33% |
| 2012-06-30 | $82.36K | +40.96% |
| 2011-06-30 | $58.43K | -29.34% |
| 2010-06-30 | $82.70K | +49.18% |
| 2009-06-30 | $55.44K | +15.21% |
| 2008-06-30 | $48.12K | +17.74% |
| 2007-06-30 | $40.87K | -- |
About Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release o… Read more